Leerink analyst Roanna Ruiz raised the firm’s price target on Xeris Biopharma (XERS) to $6 from $5 and keeps an Outperform rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Biopharma price target raised to $6.50 from $5 at Craig-Hallum
- Xeris Biopharma price target raised to $4 from $3 at Piper Sandler
- Xeris Pharmaceuticals: Strong Growth Potential and Financial Stability Justify Buy Rating
- Xeris Biopharma price target raised to $8 from $6.60 at H.C. Wainwright
- Xeris Biopharma Reports Record Revenue and Strong 2025 Outlook
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue